Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
3 reports, 1 independent
Updated Oct 1
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA accepted Alvotech's BLA for AVT80 review.1 source
Alvotech lists on Nasdaq while seeking FDA approval for biosimilar applications.1 source
Keep exploring
The entities involved
Related events
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- BOK Financial Corporation stock is publicly traded on the NASDAQ exchange.
- Materialise listed its shares on the Nasdaq stock exchange on August 27, 2026.
- INmune Bio Inc. listed its shares on the stock exchange on July 9, 2026.
- Innovation Beverage Group Ltd, based in Sydney, is listed on the Nasdaq Stock Market and operates under U.S. SEC rules.